Nature Communications (Oct 2018)
Synthetic lethality between HER2 and transaldolase in intrinsically resistant HER2-positive breast cancers
- Yi Ding,
- Chang Gong,
- De Huang,
- Rui Chen,
- Pinpin Sui,
- Kevin H. Lin,
- Gehao Liang,
- Lifeng Yuan,
- Handan Xiang,
- Junying Chen,
- Tao Yin,
- Peter B. Alexander,
- Qian-Fei Wang,
- Er-Wei Song,
- Qi-Jing Li,
- Kris C. Wood,
- Xiao-Fan Wang
Affiliations
- Yi Ding
- Department of Pharmacology and Cancer Biology, Duke University Medical Center
- Chang Gong
- Breast Tumor Center, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University
- De Huang
- Department of Pharmacology and Cancer Biology, Duke University Medical Center
- Rui Chen
- Department of Pharmacology and Cancer Biology, Duke University Medical Center
- Pinpin Sui
- Key Laboratory of Genomic and Precision Medicine, Collaborative Innovation Center of Genetics and Development, Beijing Institute of Genomics, Chinese Academy of Sciences
- Kevin H. Lin
- Department of Pharmacology and Cancer Biology, Duke University Medical Center
- Gehao Liang
- Breast Tumor Center, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University
- Lifeng Yuan
- Department of Pharmacology and Cancer Biology, Duke University Medical Center
- Handan Xiang
- Department of Pharmacology and Cancer Biology, Duke University Medical Center
- Junying Chen
- Breast Tumor Center, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University
- Tao Yin
- Department of Pharmacology and Cancer Biology, Duke University Medical Center
- Peter B. Alexander
- Department of Pharmacology and Cancer Biology, Duke University Medical Center
- Qian-Fei Wang
- Key Laboratory of Genomic and Precision Medicine, Collaborative Innovation Center of Genetics and Development, Beijing Institute of Genomics, Chinese Academy of Sciences
- Er-Wei Song
- Breast Tumor Center, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University
- Qi-Jing Li
- Department of Immunology, Duke University Medical Center
- Kris C. Wood
- Department of Pharmacology and Cancer Biology, Duke University Medical Center
- Xiao-Fan Wang
- Department of Pharmacology and Cancer Biology, Duke University Medical Center
- DOI
- https://doi.org/10.1038/s41467-018-06651-x
- Journal volume & issue
-
Vol. 9,
no. 1
pp. 1 – 11
Abstract
Resistance to anti-HER2 therapy in breast cancer remains a major obstacle in the clinic. Here the authors performed a CRISPR-selective vulnerability screen to identify transaldoloase as a target that is synthetically lethal with HER2 inhibition in breast cancer cells.
